| Biotechnology Industry | Healthcare Sector | Dr. Steven Theriault B.Sc., M.Sc., Ph.D. CEO | NEO-L Exchange | - ISIN |
| Canada Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Cytophage Technologies Ltd. is an innovative biotechnology company that focuses on the research, development, and commercialization of bacteriophage therapies. These therapies are designed to combat bacterial infections that impact human health, animal health, and food security. Based in Winnipeg, Canada, Cytophage Technologies is at the forefront of using bacteriophages, viruses that infect and destroy bacteria, as a means to address some of the most pressing health concerns today. Their work includes developing products aimed at improving poultry health, ensuring food safety, treating bovine mastitis, and offering solutions for livestock producers to manage bacterial infections more effectively.
Cytophage's AviPhage line of products is targeted towards the poultry industry. These products are designed to prevent and treat bacterial infections in poultry, thereby improving the overall health of birds and enhancing poultry production efficiency.
The PhageFend range focuses on food safety, offering solutions to combat bacterial contaminants in the food supply chain. By leveraging bacteriophage technologies, PhageFend aims to reduce the presence of harmful bacteria in food products, ensuring safer consumption for end-users.
Addressing the issue of bovine mastitis, an infection of the mammary glands in dairy cows, BoviPhage products offer a bacteriophage-based therapy. This application ensures dairy herds remain healthy and productive, ultimately benefiting dairy farmers by reducing the impact of this prevalent condition.
FarmPhage products offer a water-soluble solution for livestock producers. This innovative approach allows for the easy administration of bacteriophage therapies to livestock through their drinking water, aiding in the prevention and treatment of bacterial infections across a range of animal species.